Intercept Pharmaceuticals Current Ratio 2011-2021 | ICPT

Intercept Pharmaceuticals current ratio from 2011 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Intercept Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.49B $0.15B 3.39
2021-03-31 $0.49B $0.15B 3.33
2020-12-31 $0.55B $0.18B 3.05
2020-09-30 $0.56B $0.16B 3.44
2020-06-30 $0.61B $0.16B 3.71
2020-03-31 $0.63B $0.15B 4.19
2019-12-31 $0.72B $0.16B 4.45
2019-09-30 $0.77B $0.14B 5.49
2019-06-30 $0.82B $0.13B 6.54
2019-03-31 $0.40B $0.11B 3.72
2018-12-31 $0.48B $0.11B 4.22
2018-09-30 $0.53B $0.09B 5.98
2018-06-30 $0.58B $0.09B 6.51
2018-03-31 $0.36B $0.08B 4.58
2017-12-31 $0.45B $0.10B 4.31
2017-09-30 $0.52B $0.09B 5.95
2017-06-30 $0.58B $0.09B 6.61
2017-03-31 $0.64B $0.07B 8.74
2016-12-31 $0.71B $0.08B 9.02
2016-09-30 $0.80B $0.06B 14.57
2016-06-30 $0.51B $0.10B 4.95
2016-03-31 $0.58B $0.10B 5.79
2015-12-31 $0.64B $0.05B 13.55
2015-09-30 $0.70B $0.03B 21.83
2015-06-30 $0.74B $0.02B 31.15
2015-03-31 $0.41B $0.02B 22.61
2014-12-31 $0.25B $0.02B 16.13
2014-09-30 $0.28B $0.02B 16.92
2014-06-30 $0.31B $0.01B 25.72
2014-03-31 $0.14B $0.29B 0.48
2013-12-31 $0.15B $0.01B 16.62
2013-09-30 $0.16B $0.01B 21.08
2013-06-30 $0.16B $0.01B 22.82
2013-03-31 $0.11B $0.01B 10.98
2012-12-31 $0.11B $0.01B 8.62
2012-09-30 $0.04B $0.01B 6.32
2012-06-30 $0.00B 0.00
2012-03-31 $0.00B 0.00
2011-12-31 $0.02B $0.00B 4.69
2011-09-30 $0.00B 0.00
2010-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.520B $0.313B
Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC). Intercept Pharmaceuticals Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71